Switching HIV medication for newcomers to Quebec
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study looks at switching HIV medication to a single pill called B/F/TAF (bictegravir/emtricitabine/tenofovir alafenamide) for people who have recently moved to Canada and are new to this clinic. It aims to make HIV care simpler and more convenient for newcomers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have HIV (type 1).
- You are new to this clinic (your first visit there).
- You were born outside Canada and moved to Quebec within the last 2 years, from another country or province.
- You have taken or are currently taking HIV medication (ART).
- If you are a woman who could become pregnant, you must have a negative pregnancy test and agree not to become pregnant for a year. If you cannot become pregnant, that's fine too.
- You must not be pregnant, breastfeeding, or have certain serious health conditions like active tuberculosis, severe liver or kidney problems, or recent acute hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This study tests two ways to simplify your HIV and hepatitis B treatment while keeping the viruses controlled. By switching to a simpler combination, the goal is to maintain low viral levels and reduce the number of medicines you take.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.